Who are Imiquimod 5% Topical Cream's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Aldara (imiquimod) cream, 5%, Aldara Cream 5%, Imiquimod and Interferon alpha, Zyclara®, Imiquimod 3.75% Cream, standard dose of HCQ.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/imiquimod-5-topical-cream.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Imiquimod 5% Topical Cream — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Imiquimod 5% Topical Cream (Imiquimod 5% Topical Cream) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Toll-like receptor 7 (TLR7) agonist. Area: Dermatology/Oncology.

marketed Toll-like receptor 7 (TLR7) agonist TLR7 Dermatology/Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Imiquimod 5% Topical Cream (Imiquimod 5% Topical Cream) — University of Michigan. Imiquimod is a toll-like receptor 7 (TLR7) agonist that activates innate immune responses to enhance local antiviral and antitumor immunity.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Imiquimod 5% Topical Cream TARGET	Imiquimod 5% Topical Cream	University of Michigan	marketed	Toll-like receptor 7 (TLR7) agonist	TLR7
Aldara (imiquimod) cream, 5%	Aldara (imiquimod) cream, 5%	Graceway Pharmaceuticals, LLC	marketed	TLR7 agonist	TLR7 (Toll-like receptor 7)
Aldara Cream 5%	Aldara Cream 5%	Hordinsky, Maria K., MD	marketed	Toll-like receptor 7 (TLR7) agonist	TLR7
Imiquimod and Interferon alpha	Imiquimod and Interferon alpha	The University of Texas Health Science Center, Houston	marketed	Immunostimulant combination	TLR7/8 (imiquimod); Interferon-alpha receptor (interferon alpha)
Zyclara®	Zyclara®	Actavis Inc.	marketed	Toll-like receptor agonist	TLR7, TLR8
Imiquimod 3.75% Cream	Imiquimod 3.75% Cream	Medical University of Graz	marketed	TLR7 agonist	TLR7 (Toll-like receptor 7)
standard dose of HCQ	standard dose of HCQ	University of Sao Paulo General Hospital	marketed	Antimalarial immunosuppressant	Toll-like receptors (TLR7, TLR9); phospholipase C

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Toll-like receptor 7 (TLR7) agonist class)

Hordinsky, Maria K., MD · 1 drug in this class
University Medical Centre Maribor · 1 drug in this class
University of Michigan · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Imiquimod 5% Topical Cream — Competitive Intelligence Brief. https://druglandscape.com/ci/imiquimod-5-topical-cream. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab